Literature DB >> 29134134

Predicting the Real-World Future of Glaucoma Patients? Cautions Are Required for Machine Learning.

Erping Long1, Peixing Wan1, Yehong Zhuo1.   

Abstract

Entities:  

Year:  2017        PMID: 29134134      PMCID: PMC5678552          DOI: 10.1167/tvst.6.6.3

Source DB:  PubMed          Journal:  Transl Vis Sci Technol        ISSN: 2164-2591            Impact factor:   3.283


× No keyword cloud information.
We read with great interest the recent article by Yuki et al.[1] It is very thought-provoking that the authors predicted the likelihood of a future motor vehicle collision (MVC) among patients with primary open-angle glaucoma (POAG) based on multiple attributes using the penalized support vector machine (pSVM). However, several points remain to be discussed in terms of model design, data interpretation, as well as clinical application. On one hand, the design of the model is somewhat controversial (recapitulation in Fig. 1A). The high-dimensional dataset (62 variables in the predpenSVM_basic model and 84 variables in the predSVM and predpenSVM_all models) is inclined to overfit when the sample size is small, because the cover range is not sufficient for pattern recognition on each attribute.[2] Elaboration of attributes' contribution is a promising alternative to address this issue. Model simplification (excluding the less contributed attributes) will broaden dramatically the application merit and be more cost-effective. Moreover, the progress of POAG and corresponding controlling efficacy have been reported to exhibit great heterogeneity.[3] Thus, potential indictors regarding intraocular pressure, visual field, and drug intake should be included. Given that best-corrected visual acuity has a significant effect on the likelihood of MVC, other variables of visual function, including refractive conditions, stereoscopic vision, contrast sensitivity, and color vision, can improve the model performance as well.[4,5]
Figure 1

Overall suggestions on the design, verification, and interpretation of study. (A) For the model design, elaboration of the variables' contribution and model simplification will broaden the application merit dramatically. Moreover, potential indictors regarding the progress of POAG, controlling efficacy, and comprehensive indices of visual function can improve the model performance further. (B) For the model validation and clinical merit, the variety among areas and generations should be investigated and stratified. Besides, customized classifiers and a shorter-period prediction could provide direct and practical guideline for real-world decision making.

Overall suggestions on the design, verification, and interpretation of study. (A) For the model design, elaboration of the variables' contribution and model simplification will broaden the application merit dramatically. Moreover, potential indictors regarding the progress of POAG, controlling efficacy, and comprehensive indices of visual function can improve the model performance further. (B) For the model validation and clinical merit, the variety among areas and generations should be investigated and stratified. Besides, customized classifiers and a shorter-period prediction could provide direct and practical guideline for real-world decision making. On the other hand, the model validation and its clinical merit should be interpreted cautiously (recapitulation in Fig. 1B). First concern lies in the consistency of predicted results among patients at the three involved centers. Differences should be evaluated carefully to investigate whether this predictive model could be extended to patients at other centers or areas. Second, the age range (with a span of above 40 years) should be stratified before modeling due to the distinct behavioral pattern and life-styles among different generations.[6] Third, the predicted outcome is equivocal; it is unclear whether intervention should be conducted based on a probability. Alternatively, the classification outcome could provide direct and reliable guidelines.[7] Classifiers also could be customized to fit in various real-world situations: loose thresholds for better sensitivity in wide-range primary screening and more rigorous thresholds when making vital decision.[8] Fourth, the predictive power varies within different time frames: it is easier to achieve strong predictive performance within the first year than within 3 years. It also is a dilemma for decision-making when facing a likely incident within a 3-year period: when will the incident happen within this span of 3 years? Should all these high-risk patients be disqualified? Therefore, a shorter-period prediction will be more practical and cost-efficient. Machine lea rning for prediction promises to transform health care.[9] However, in the “hype cycle” of emerging technologies, machine learning currently rides atop the “peak of inflated expectations”[10] Therefore, the capabilities and limitations of this technology should be validated and acknowledged more cautiously. Although we are conservative about the effect of the model, we appreciate the remarkable contribution made by Yuki and hope our suggestions on the design, verification and interpretation will help this work move toward real-world application.
  8 in total

1.  The problem of overfitting.

Authors:  Douglas M Hawkins
Journal:  J Chem Inf Comput Sci       Date:  2004 Jan-Feb

2.  Comparison of vision-related quality of life in primary open-angle glaucoma and dry-type age-related macular degeneration.

Authors:  S Karadeniz Ugurlu; A E Kocakaya Altundal; M Altin Ekin
Journal:  Eye (Lond)       Date:  2016-11-04       Impact factor: 3.775

3.  Machine Learning and Prediction in Medicine - Beyond the Peak of Inflated Expectations.

Authors:  Jonathan H Chen; Steven M Asch
Journal:  N Engl J Med       Date:  2017-06-29       Impact factor: 91.245

4.  Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.

Authors:  Steven M Kymes; Michael A Kass; Douglas R Anderson; J Philip Miller; Mae O Gordon
Journal:  Am J Ophthalmol       Date:  2006-06       Impact factor: 5.258

Review 5.  Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects.

Authors:  Claudio Cedrone; Raffaele Mancino; Angelica Cerulli; Massimo Cesareo; Carlo Nucci
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

6.  Predicting the Future - Big Data, Machine Learning, and Clinical Medicine.

Authors:  Ziad Obermeyer; Ezekiel J Emanuel
Journal:  N Engl J Med       Date:  2016-09-29       Impact factor: 91.245

7.  The Association of Refractive Error with Glaucoma in a Multiethnic Population.

Authors:  Ling Shen; Ronald B Melles; Ravikanth Metlapally; Lisa Barcellos; Catherine Schaefer; Neil Risch; Lisa J Herrinton; Christine Wildsoet; Eric Jorgenson
Journal:  Ophthalmology       Date:  2015-08-08       Impact factor: 12.079

8.  Predicting Future Self-Reported Motor Vehicle Collisions in Subjects with Primary Open-Angle Glaucoma Using the Penalized Support Vector Machine Method.

Authors:  Kenya Yuki; Ryo Asaoka; Sachiko Awano-Tanabe; Takeshi Ono; Daisuke Shiba; Hiroshi Murata; Kazuo Tsubota
Journal:  Transl Vis Sci Technol       Date:  2017-06-02       Impact factor: 3.283

  8 in total
  2 in total

1.  Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic.

Authors:  Brian C Stagg; Joshua D Stein; Felipe A Medeiros; Barbara Wirostko; Alan Crandall; M Elizabeth Hartnett; Mollie Cummins; Alan Morris; Rachel Hess; Kensaku Kawamoto
Journal:  Ophthalmol Glaucoma       Date:  2020-08-15

Review 2.  Miniaturization in Glaucoma Monitoring and Treatment: A Review of New Technologies That Require a Minimal Surgical Approach.

Authors:  H Burkhard Dick; Tim Schultz; Ronald D Gerste
Journal:  Ophthalmol Ther       Date:  2019-02-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.